B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways

Blood. 2012 Sep 20;120(12):2529-36. doi: 10.1182/blood-2012-06-438911. Epub 2012 Aug 14.

Abstract

Recent data reveal an important role for B cells in the pathogenesis of chronic GVHD (cGVHD). Patients with cGVHD have delayed B-cell reconstitution and elevated BAFF to B-cell ratios compared to patients without cGVHD. The mechanisms promoting and sustaining B-cell activation in this disease, however, remain unknown. As BAFF increases murine B-cell metabolism and survival and maintains autoreactive B-cell clones, we performed ex vivo analyses of peripheral B cells from 51 patients who either had or did not have active cGVHD and were greater than 1 year from the time of allogeneic hematopoietic stem cell transplantation. We found that B cells from patients with active cGVHD were in a heightened metabolic state and were resistant to apoptosis. Exogenous BAFF treatment amplified cell size and survival in B cells from these patients. We found significantly increased signaling through ERK and AKT that associated with decreased levels of proapoptotic Bim, suggesting a mechanistic link between elevated BAFF levels and aberrant B-cell survival. Thus, we identify a role for BAFF in the pathogenesis of cGVHD and define B-cell activation and survival pathways suitable for novel therapeutic development in cGVHD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Apoptosis*
  • B-Cell Activating Factor / immunology
  • B-Cell Activating Factor / metabolism*
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Cell Size
  • Cells, Cultured
  • Chronic Disease
  • Female
  • Flow Cytometry
  • Follow-Up Studies
  • Graft vs Host Disease / etiology*
  • Graft vs Host Disease / pathology
  • Graft vs Host Disease / therapy
  • Hematologic Neoplasms / complications*
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunoblotting
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Signal Transduction*
  • Transplantation, Homologous
  • Young Adult

Substances

  • B-Cell Activating Factor
  • TNFSF13B protein, human